Adaptimmune

13.03.2023 • News

Adaptimmune and TCR2 Agree Merger

Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating solid tumors” with projected sales of about $27 billion by 2026.

05.03.2015 • News

Adaptimmune Strengthens Management Team with Key Executive Hires

05.06.2014 • News

Adaptimmune in Cancer Collaboration With GlaxoSmithKline

Top-Feature

Evonik Industries AG

Maximize the Potential of Spent Hydroprocessing Catalysts

Ecocool GmbH

Transport Logistic: Ecocool Presents Packaging Solutions for Pharmaceutical Transports

CHEManager International c/o Wiley-VCH GmbH

Digitalization in the Chemical Industry

IMCD Deutschland GmbH

Fostering Innovation and Collaboration

Interview

Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.